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The 2014/15 influenza season in the United Kingdom (UK) was characterised by circulation 
of predominantly antigenically and genetically drifted influenza A(H3N2) and B viruses. A 
universal paediatric influenza vaccination programme using a quadrivalent live attenuated 
influenza vaccine (LAIV) has recently been introduced in the UK. This study aims to measure 
the end-of-season influenza vaccine effectiveness (VE), including for LAIV, using the test 
negative case–control design. The overall adjusted VE against all influenza was 34.3% (95% 
confidence interval (CI) 17.8 to 47.5); for A(H3N2) 29.3% (95% CI: 8.6 to 45.3) and for B 
46.3% (95% CI: 13.9 to 66.5). For those aged under 18 years, influenza A(H3N2) LAIV VE was 
35% (95% CI: −29.9 to 67.5), whereas for influenza B the LAIV VE was 100% (95% CI:17.0 to 
100.0). Although the VE against influenza A(H3N2) infection was low, there was still 
evidence of significant protection, together with moderate, significant protection against 
drifted circulating influenza B viruses. LAIV provided non-significant positive protection 
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against influenza A, with significant protection against B. Further work to assess the 
population impact of the vaccine programme across the UK is underway. 
Introduction 
The United Kingdom (UK) has a longstanding selective influenza vaccination programme 
targeting individuals at an increased risk of developing severe disease following infection. This 
has been undertaken with a wide range of inactivated influenza vaccines that are available on 
the UK market. In 2013/14, the phased roll-out of a universal childhood influenza vaccination 
programme with a newly licensed live attenuated influenza vaccine (LAIV) commenced. In 
2014/15, all two, three and four year olds, children of school age (see below for details across 
the countries of the UK) and children aged from six months to 18 years of age in a clinical risk 
group, who did not have any contraindications to receive LAIV, were offered a quadrivalent 
LAIV. Influenza vaccine is offered to those groups older than six months of age with underlying 
clinical disease such as chronic heart or respiratory disease that put the patient at increased 
risk of serious illness from influenza or where influenza may exacerbate the underlying disease 
itself. For healthy school age children, different parts of the UK targeted different groups [1]: 
all primary school age children in Scotland and Northern Ireland; primary school and 
secondary school age children (11–13 years) in pilot areas in England and children aged 11–
12 years in Wales. Adults in a target group are offered one of the inactivated vaccines available 
in the UK. In February 2014, northern hemisphere 2014/15 influenza vaccines were 
recommended by the World Health Organization (WHO) to contain the following 
components: an A/California/7/2009 (H1N1)pdm09-like virus; an A/Texas/50/2012 (H3N2)-
like virus and a B/Massachusetts/2/2012-like B/Yamagata-lineage virus, plus a 
B/Brisbane/60/2008-like B/Victoria-lineage virus for quadrivalent vaccines [2]. 
Moderate levels of influenza activity circulated in the community in the UK in 2014/15, with 
influenza A(H3N2) the dominant strain for the majority of the season from December 2014, 
and influenza B from February to April 2015 [3]. The community impact of influenza A(H3N2) 
virus was predominantly seen in the elderly, with numerous outbreaks in care homes [3]. 
Admissions to hospital and intensive care units (ICU) were also observed though with some 
evidence of variation across the UK, with peak ICU numbers higher in England than in recent 
seasons and levels of excess mortality, particularly in the elderly, higher in England than the 
influenza season of 2008/09 when A(H3N2) was also the dominant subtype [3]. 
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As in many northern hemisphere countries, the 2014/15 season was characterised by the 
emergence of A(H3N2) strains that were antigenically and genetically drifted from the 
2014/15 H3N2 vaccine strain, A/Texas/50/2012 and more closely related to the 
A/Switzerland/9715293/2013 virus, the vaccine strain recommended for the forthcoming 
2015/16 season [4]. Indeed, an interim mid-season UK estimate of seasonal influenza vaccine 
effectiveness (VE) calculated in January 2015 showed a low effectiveness of 3.4% (95% 
CI: −44.8 to 35.5) against laboratory-confirmed influenza infection in primary care [5]. Later in 
the season, influenza B viruses circulated, with the majority antigenically and genetically 
distinguishable from the northern hemisphere 2014/15 B/Yamagata-lineage vaccine strain 
[3]. 
This study reports the final end-of-season VE findings for the 2014/15 seasonal influenza 
vaccine in preventing medically attended laboratory confirmed influenza A(H3N2) and B using 
the established primary care sentinel swabbing surveillance schemes across the UK by sub-
type and age group [5,6]. In addition, the study examines the potential protective effect of 
vaccination of children (< 18 years of age) using the newly licensed intranasally administered 
LAIV compared with the inactivated, injectable influenza vaccines, in a season when drifted 
strains circulated. 
Methods 
Study population and period 
Data were obtained from five primary care influenza sentinel swabbing surveillance schemes 
in the UK from England (two schemes), Scotland, Wales and Northern Ireland. Details of the 
Royal College of General Practitioners (RCGP), Public Health England (PHE) Specialist 
Microbiology Network (SMN), Public Health Wales, Public Health Agency (PHA) of Northern 
Ireland and Health Protection Scotland (HPS) swabbing schemes have been published 
previously [6]. 
The study period ran from 1 October 2014 to 17 April 2015. A convenience sample of patients 
presenting with an influenza-like illness (ILI) were swabbed as part of clinical care, after having 
given verbal consent. Cases were defined as persons presenting during the study period in a 
participating General Practitioner (GP) practice with an ILI, who were swabbed and then 
tested positive for influenza A or B. ILI was clinically defined as an individual presenting in 
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primary care with an acute respiratory illness with physician-diagnosed fever or complaint of 
feverishness in the previous seven days. Controls were individuals presenting with ILI in the 
same period that were swabbed and tested negative for influenza. 
A standardised questionnaire was completed by the GP while swabbing the patient during the 
consultation. Demographic, clinical and epidemiological information was collected from cases 
and controls, including date of birth, sex, defined underlying clinical risk group, date of onset 
of respiratory illness, date of specimen collection, and influenza vaccination status for the 
2014/15 season with vaccination dates. Information was collected on whether the vaccine 
was administered by injection or intranasally, with injection a proxy for inactivated influenza 
vaccine (IIV) and intranasal administration, a proxy for LAIV. 
Laboratory methods 
Samples in England were sent to the PHE Microbiology Services, Colindale (RCGP scheme) or 
one of the specialist PHE microbiology laboratories (SMN scheme). Samples in Northern 
Ireland were sent to the Regional Virus Laboratory, Belfast, in Scotland to the West of Scotland 
Specialist Virology Centre, Glasgow (HPS scheme), and in Wales to the Public Health Wales 
Specialist Virology Centre, Cardiff. All these laboratories participate in the UK Influenza 
Testing Laboratory Network and undertake testing annually of PHE molecular influenza 
detection external quality assurance scheme panels [7]. Laboratory confirmation of study 
samples was undertaken using comparable methods with real-time PCR (RT-PCR) assays 
capable of detecting circulating influenza A and influenza B viruses and other respiratory 
viruses [8,9]. Further strain characterisation was also performed; influenza viruses were 
isolated in MDCK or MDCK-SIAT1 cells from RT-PCR positive samples from England as 
previously described [10,11]. Influenza virus isolates with a haemagglutination titre ≥ 40 were 
characterised antigenically using post-infection ferret antisera in haemagglutination 
inhibition (HI) assays, with guinea pig or turkey red blood cells [12]. 
Nucleotide sequencing of the haemagglutinin (HA) gene of a subset of influenza A(H3N2) 
viruses with H3 subtype PCR detection cycle threshold (Ct) values ≤ 32, was undertaken. The 
samples selected were representative of vaccination status, date of sample collection, 
geographical location and antigenic characterisation (when available) across the study period. 
Sequencing was performed using an influenza A full genome amplification protocol [13] for 
sequencing on an Illumina MiSeq sequencer. 
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A phylogenetic tree was constructed with a neighbour-joining algorithm available in the Mega 
6 software (http://www.megasoftware.net) [10]. HA sequences from reference strains used 
in the phylogenetic analysis were obtained from the EpiFlu database of the Global Initiative 
on Sharing Avian Influenza Data (GISAID) (Table 1).  
TABLE 1. Details of influenza A(H3N2) haemagglutinin sequences obtained from GISAID 
used in the phylogenetic analysis  
Virus isolate Segment 
ID/Accession 
number 
Country Collection 
date (year-
month-day) 
Originating 
laboratory 
Submitting laboratory 
A/Hong Kong/5738/2014 EPI539806 China 2014-04-30 Government 
Virus Unit, 
Hong Kong 
(SAR) 
National Institute for 
Medical Research, 
London, UK 
A/Switzerland/9715293/2013 EPI530687 Switzerland 2013-12-06 Hopital 
Cantonal 
Universitaire 
de Geneves, 
Switzerland 
National Institute for 
Medical Research, 
London, UK 
A/Samara/73/2013 EPI460558 Russian 
Federation 
2013-03-12 WHO 
National 
Influenza 
Centre, Saint 
Petersburg, 
Russian 
Federation 
National Institute for 
Medical Research, 
London, UK 
A/Texas/50/2012 EPI391247 United States 2012-04-15 Texas 
Department 
of State 
Health 
Services, 
Austin, USA 
Centers for Disease 
Control and 
Prevention, Atlanta, 
USA 
A/AthensGR/112/2012 EPI358885 Greece 2012-02-01 Hellenic 
Pasteur 
Institute, 
Athens, 
Greece 
National Institute for 
Medical Research, 
London, UK 
A/Stockholm/18/2011 EPI326139 Sweden 2011-03-28 Swedish 
Institute for 
Infectious 
Disease 
Control, 
Solna, 
Sweden 
National Institute for 
Medical Research, 
London, UK 
A/Perth/16/2009 EPI211334 Australia/ 
Western 
Australia 
2009 (month 
and day 
unknown) 
WHO 
Collaboratin
g Centre for 
Reference 
and 
Research on 
Influenza, 
Melbourne, 
Centers for Disease 
Control and 
Prevention, Atlanta, 
USA 
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Australia 
A/Glasgow/400003/2015 EPI175027 United Kingdom 
 
2015-01-02 Gart Naval 
General 
Hospital, 
Glasgow, UK 
National Institute for 
Medical Research, 
London, UK 
A/Glasgow/400097/2015 EPI175028 2015-01-02 
A/Glasgow/400580/2014 EPI175029 2014-12-26 
A/Glasgow/401673/2014 EPI175030 2014-12-29 
A/Glasgow/401674/2015 EPI175031 2015-01-01 
A/Glasgow/401678/2015 EPI175032 2015-01-07 
A/Glasgow/431929/2014 EPI175077 2014-11-23 
GISAID: Global Initiative on Sharing All Influenza Data; UK: United Kingdom; USA: United States of America; 
WHO: World Health Organization. 
The England HA sequences obtained in this study, which were also used in the phylogenetic 
analysis, were deposited in GISAID under the following accession numbers: EPI607577, 
EPI607585, EPI607593, EPI607601, EPI607609, EPI607617, EPI607625, EPI607633, EPI607641, 
EPI607649, EPI607657, EPI607665, EPI607673, EPI607681, EPI607689, EPI607697, EPI607705, 
EPI607713, EPI607721, EPI607729, EPI607737, EPI607745, EPI607753, EPI607761, EPI607769, 
EPI607777, EPI607785, EPI607793, EPI607801, EPI607809, EPI607817, EPI607825, EPI607833, 
EPI607841, EPI607849, EPI607857, EPI607865, EPI607873, EPI607881, EPI607889, EPI607899, 
EPI607914, EPI607930, EPI607945, EPI607960, EPI607975, EPI607990, EPI608006, 
EPI608022EPI608038, EPI608051, EPI608067. 
Statistical methods 
Persons were defined as vaccinated if the date of vaccination with the 2014/15 influenza 
vaccine (either inactivated or live attenuated) was 14 or more days before onset of illness. To 
take into account the time taken for an immune response, those in whom the period between 
vaccination and onset of illness was less than 14 days, were excluded from the analysis. Those 
with a missing date of onset or an onset date more than seven days before the swab was 
taken, were excluded. 
VE was estimated by the test–negative case–control (TNCC) design. In this design, VE is 
calculated as 1-(odds ratio, OR) obtained using multivariable logistic regression models with 
influenza A and B RT-PCR results as outcomes, and seasonal vaccination status as the linear 
predictor. No analysis was conducted for influenza A(H1N1)pdm09 because of the small 
number of cases. In the analyses evaluating VE for a specific type or subtype, those positive 
for other types/subtypes were excluded. Age (coded into four standard age groups, < 18, 18–
44, 45–64 and ≥ 65 years), sex, clinical risk group, surveillance scheme (RCGP, SMN, Scotland, 
Wales, Northern Ireland), pilot area and date of sample collection (month) were investigated 
as potential confounding variables. Pilot area was defined as those parts of the UK where 
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primary school-age vaccination was undertaken (England primary pilot areas, Scotland and 
Northern Ireland - all primary school age children). To investigate whether the VE changed in 
relation to time since vaccination, analyses stratifying VE by time since vaccination (less 
than three months, three months or longer) and by period (October to January, February to 
April) were undertaken. Where date of vaccination was not given, time since vaccination was 
estimated based on the assumption that vaccination occurred at the median vaccination date 
of 15 October 2014, and also treated as missing in a sensitivity analysis. VE was also assessed 
stratified by age group and scheme with differences in VE assessed by a likelihood ratio test 
between groups where numbers were not too low for a precise estimate. In addition, an 
analysis was performed just in those aged ≥18 years (in whom IIV would have been given). 
Finally, to estimate the VE for LAIV, an estimate was obtained in those aged under 18 years as 
well as for two, three and four year olds who had received the intranasal vaccine. A sensitivity 
analysis was undertaken to include all samples dropped from the main analysis due to late 
sampling (more than seven days after onset). A regression analysis was undertaken to 
compare the viral load using the Ct values for H3 detection by PCR in vaccinated and 
unvaccinated A(H3N2) laboratory-confirmed cases in samples from the RCGP scheme in 
England. 
All statistical analyses were carried out in Stata version 13 (StataCorp, College Station, Texas). 
Results 
A total of 4,442 individuals were swabbed in primary care during the study period. For the VE 
analysis, 116 were excluded due to missing vaccination status, 277 due to missing date of 
onset, 922 because they were swabbed more than seven days after onset, 77 because they 
were vaccinated within 14 days of onset and five because of vaccine (LAIV) contamination of 
samples (Figure 1). 
FIGURE 1. Swabbing results of ILI patients in primary care in the United Kingdom, October 
2014 to April 2015 (n=4,442)  
ILI: influenza-like illness; LAIV: live attenuated influenza vaccine. 
The details of those remaining in the study (n=2,931) are given in Table 2 according to the 
swab result. Positivity rates differed significantly by surveillance scheme, interval from onset 
and pilot area. 
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TABLE 2. Details for influenza A and B cases (n=902) and controls (n=2,029), United 
Kingdom, October 2014 to April 2015 
 
Controls 
(n = 2,029) 
B 
(n = 184) 
A(H1N1) 
(n = 60) 
A(H3N2) 
(n = 629) 
A (untyped) 
(n = 31) 
P valuea 
n (%) n (%) n (%) n (%) n (%) 
Age group (years) 0.062 
< 18 507 (72.3) 33 (4.7) 16 (2.3) 142 (20.3) 4 (0.6)  
18–44 770 (69.1) 60 (5.4) 27 (2.4) 244 (21.9) 16 (1.4)  
45–64 502 (66.1) 79 (10.4) 16 (2.1) 157 (20.7) 6 (0.8)  
≥ 65 250 (71) 12 (3.4) 1 (0.3) 84 (23.9) 5 (1.4)  
Missing information 0 (0) 0 (0) 0 (0) 2 (100) 0 (0)  
Sex      0.077 
Female 1,198 (70.6) 101 (5.9) 34 (2) 352 (20.7) 14 (0.8)  
Male 822 (67.5) 83 (6.8) 26 (2.1) 271 (22.2) 17 (1.4)  
Missing 9 (60) 0 (0) 0 (0) 6 (40) 0 (0)  
Surveillance scheme      < 0.001 
Northern Ireland 67 (55.4) 9 (7.4) 2 (1.7) 28 (23.1) 15 (12.4)  
RCGP 832 (65.5) 100 (7.9) 40 (3.1) 300 (23.6) 0 (0)  
SMN 235 (75.1) 15 (4.8) 3 (1) 54 (17.3) 6 (1.9)  
Scotland 867 (74) 60 (5.1) 15 (1.3) 221 (18.9) 10 (0.9)  
Wales 28 (51.9) 0 (0) 0 (0) 26 (48.1) 0 (0)  
Risk groupb      0.473 
No 1,376 (68.7) 149 (7.4) 48 (2.4) 416 (20.8) 17 (0.8)  
Yes 479 (70.1) 28 (4.1) 6 (0.9) 158 (23.1) 12 (1.8)  
Missing 174 (71.3) 7 (2.9) 6 (2.5) 55 (22.5) 2 (0.8)  
Interval onset-swab (days)      < 0.001 
0–1 275 (67.1) 22 (5.4) 9 (2.2) 100 (24.4) 4 (1)  
2–4 975 (64.4) 108 (7.1) 34 (2.2) 380 (25.1) 20 (1.3)  
5–7 779 (77.4) 54 (5.4) 17 (1.7) 149 (14.8) 7 (0.7)  
Month       
October 222 (94.9) 2 (0.9) 2 (0.9) 7 (3) 1 (0.4) < 0.001 
November 354 (94.4) 6 (1.6) 0 (0) 15 (4) 0 (0)  
December 417 (65.1) 4 (0.6) 6 (0.9) 209 (32.6) 5 (0.8)  
January 476 (61.7) 20 (2.6) 19 (2.5) 251 (32.5) 7 (0.9)  
February 311 (59.7) 51 (9.8) 17 (3.3) 128 (24.6) 14 (2.7)  
March 198 (64.1) 77 (24.9) 14 (4.5) 17 (5.5) 4 (1.3)  
April 51 (64.6) 24 (30.4) 2 (2.5) 2 (2.5) 0 (0)  
Vaccination status      0.104 
Unvaccinated 1,507 (68.5) 151 (6.9) 53 (2.4) 469 (21.3) 21 (1)  
Vaccinated (14–91 days ago) 293 (73.8) 6 (1.5) 1 (0.3) 93 (23.4) 4 (1)  
Vaccinated(> 91 days ago) 229 (68.4) 27 (8.1) 6 (1.8) 67 (20) 6 (1.8)  
Pilot area      0.002 
No 725 (65.8) 91 (8.3) 28 (2.5) 253 (23) 6 (0.5)  
Yes 1,272(71.2) 91 (5.1) 32 (1.8) 368 (20.6) 25 (1.4)  
Missing 32(76.2) 2 (4.8) 0 (0) 8 (19) 0 (0)  
Vaccine administration 
method (under 18 only)      
0.022 
Injection 11 (55) 2 (10) 0 (0) 6 (30) 1 (5)  
Intranasal 66 (80.5) 0 (0) 3 (3.7) 13 (15.9) 0 (0)  
Missing 5 (62.5) 1 (12.5) 0 (0) 2 (25) 0 (0)  
RCGP: Royal College of General Practitioners; SMN: Specialist Microbiology Network. 
Two people were positive for both influenza B and influenza A (one H1N1, one H3N2). 
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a Positive versus negative for influenza. 
b Individuals older than six months of age with underlying clinical disease such as chronic heart or respiratory 
disease that put the patient at increased risk of serious illness from influenza or where influenza may 
exacerbate the underlying disease itself. 
Strain characterisation 
During the 2014/15 season, the PHE Respiratory Virus Unit (RVU) isolated and antigenically 
characterised 84 A(H3N2) influenza viruses received through the two primary care influenza 
sentinel swabbing surveillance schemes in England. The majority were antigenically similar to 
the A/Texas/50/2012 H3N2 northern hemisphere 2014/15 vaccine strain, however 26 showed 
reduced reactivity in antigenic tests with A/Texas/50/2012 antiserum. These 26 isolates were 
antigenically similar to A/Switzerland/9715293/2013, the H3N2 virus selected for the 2015/16 
northern hemisphere influenza vaccine [2]. A/Switzerland/9715293/2013 is related to, but 
antigenically and genetically distinguishable, from the A/Texas/50/2012 vaccine virus. One 
virus isolate was antigenically similar to A/England/507/2014, a reference virus from the 3C.2a 
genetic clade. 
Genetic characterisation of A(H3N2) viruses was performed by both RVU and the West of 
Scotland laboratory. Of 118 A(H3N2) viruses from samples received through the RCGP scheme 
in England and characterised genetically by RVU, some of which did not grow sufficiently to 
be able to be antigenically characterised, and 149 A(H3N2) viruses genetically characterised 
by the West of Scotland laboratory, the majority (192; 72%) fall into the haemagglutinin (HA) 
genetic subgroup 3C.2a and 7 (3%) fall into another HA subgroup, 3C.3a; viruses from both of 
these HA genetic subgroups have been shown to be antigenically distinguishable from the 
2014/15 A(H3N2) vaccine virus [4]. The remaining 68 (25%) H3N2 viruses sequenced had HA 
genes which belong in genetic group 3C.3, which is antigenically similar to the 2014/15 
A(H3N2) vaccine virus. 
Of 45 influenza B viruses isolated and antigenically characterised as belonging to the 
B/Yamagata/16/88 lineage by RVU, 41 showed reduced reactivity in antigenic tests (≥ four-
fold difference) with antiserum to the 2014/15 northern hemisphere B/Yamagata-lineage 
trivalent and quadrivalent vaccine virus, B/Massachusetts/2/2012, with 29 of these 41 isolates 
showing significant (> four-fold difference) reduced reactivity, indicative of antigenic drift. 
These 41 isolates were antigenically similar to B/Phuket/3073/2013, the influenza 
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B/Yamagata lineage virus selected for 2015/16 northern hemisphere influenza vaccines. 
B/Phuket/3073/2013 is related to, but antigenically and genetically distinguishable, from the 
B/Massachusetts/2/2012 vaccine virus. Three influenza B viruses have been isolated and 
antigenically characterised as belonging to the B/Victoria/2/87 lineage, similar to the 
influenza B/Victoria-lineage component (B/Brisbane/60/2008) of the 2014/15 northern 
hemisphere quadrivalent vaccine. The West of Scotland laboratory genetically characterised 
184 influenza B viruses by real-time PCR; 171 (93%) fell within the B/Yamagata lineage and 13 
(7%) within the B/Victoria lineage. Of these, 37 B/Yamagata lineage viruses were sequenced 
and all genetically characterised as B/Phuket/3073/2013-like, which is antigenically 
distinguishable from the B/Yamagata vaccine virus. Four B/Victoria lineage viruses were 
genetically characterised as B/Brisbane/60/2008-like, which matches the B/Victoria lineage 
component of the quadrivalent vaccine. 
Figure 2 shows the phylogenetic characteristics of the HA of circulating A(H3N2) strains. 
FIGURE 2. Phylogenetic analysis of representative haemagglutinin sequences from United 
Kingdom influenza A(H3N2) 2014/15 viruses with reference viruses obtained from the 
GISAID EpiFlu database  
Branch lengths are drawn to scale. Amino acid changes characteristic of genetic clades/subclades are marked 
on the tree. 
Model fitting for vaccine effectiveness estimation 
When estimating vaccine effects, age group, sex, time-period (defined by month of sample 
collection), pilot area and surveillance scheme were adjusted for in a multivariable logistic 
regression model. Although all these variables were significantly associated with having a 
positive swab, only age group and time-period were confounders for the vaccine effects 
(changed the estimate by more than 5% as previously described [5,6]). Information on risk 
group was missing for 244 of 2,931 samples (8.3%) and was therefore not included in the final 
model. If risk group was included, it was found not to be associated with being positive and 
the VE estimates remained similar. 
Tables 3, 4 and 5 show vaccine effectiveness estimates against influenza A (overall), A(H3N2) 
and B in all ages, ≥ 18 year olds and < 18 year olds. The overall influenza VE was respectively 
34.3% (95% CI: 17.8 to 47.5) for all ages; 34.7% (95% CI: 16 to 49.3) for those ≥ 18 year of age 
and 25.2% (95% CI:-23.3, 54.7) for those < 18 years. Further breakdown by age is shown in 
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Table 4. 
TABLE 3. Samples positive (cases, n = 902) and negative (controls, n = 2,029) for influenza A 
and B according to vaccination status and VE estimates, United Kingdom, October 2014 to 
April 2015 
 Cases (n=902) Controls (n=2,029) Crude VE 
(95% CI) 
Adjusteda VE 
(95% CI) Vaccinated Unvaccinated Vaccinated Unvaccinated 
Influenza A or B 
 
210 692 522 1,507 12.4% 
(−5.3 to 27.1) 
34.3% 
(17.8 to 47.5) 
Influenza A 177 543 522 1,507 5.9% 
(−14.6 to 22.7) 
29.9% 
(10.5 to 45.1) 
Influenza A/H3 160 469 522 1,507 1.5% 
(−20.9 to 19.8) 
29.3% 
(8.6 to 45.3) 
Influenza B 33 151 522 1,507 36.9% 
(6.9 to 57.3) 
46.3% 
(13.9 to 66.5) 
CI: confidence interval; VE: vaccine effectiveness. 
a Adjusted for age group, sex, month, pilot area and surveillance scheme. 
TABLE 4. Adjusted vaccine effectiveness estimates for influenza by age, surveillance scheme, 
LAIV pilot area and by risk group in > 18 year olds, United Kingdom, October 2014 to April 
2015 (n = 2,228) 
Factor Level 
Adjusted VEa % (95% CI) by type 
A A(H3N2) B 
Age (years) > 18 30.4 (8.4 to 47.2) 29.4(5.8 to 47.1) 43.6(5.5 to 66.3), 
18–44 34.5 (−3.0 to 58.4) 30.3 (−12.4 to 56.7) 40.4 (−50.9 to 76.5) 
45–64 32.4 (−1.8 to 55.2) 31.1 (−5.8 to 55.2) 49.2 (−0.4 to 74.3) 
≥ 65 30.2 (−46.4 to 66.7) 32.6 (−44.5 to 68.6) −203 (−2,300 to 61.7)b 
18–64 33.4 (10.5 to 50.5) 31.2 (6.1 to 49.6) 41.9 (0.1 to 66.1) 
Scheme RCGP 41.5 (19.9 to 57.3) 37.7 (13.5 to 55.1) 24.4 (−30.2 to 56.1) 
SMN −13 (−152.6 to 49.4) −23.6 (−192.2 to 47.2) 66.2 (−79.4 to 93.6) 
Scotland 23.1 (−9.4 to 46) 19.2 (−16.2 to 43.8) 81.5 (47.2 to 93.5) 
Wales −41 (−458.6 to 64.4) −41 (−458.6 to 64.4) No influenza B 
Northern Ireland 21.7 (−150.3 to 75.5) 44.5 (−122.6 to 86.2) −18.7 (−539.4 to 78)b 
Pilot area 
Non-pilot 33.9 (1.5 to 55.7) 32.5 (−2.9 to 55.7) 34.2 (−28.4 to 66.3) 
Pilot 25.4 (−2.3 to 45.6) 24.5 (−5.3 to 45.8) 57.4 (13.8 to 78.9) 
Risk groupc 
≥ 65 or in a risk 
group 34.8 (3.1 to 56.2) 32.4 (−2.4 to 55.3) 15.5 (−107.6 to 65.6) 
In a risk group 32.5 (−3.4 to 55.9) 30.0 (−9.3 to 55.2) 40.6 (−55.6 to 77.3) 
CI: confidence interval; RCGP: Royal College of General Practitioners Research and Surveillance Centre; SMN: 
Specialist Microbiology Network; VE: vaccine effectiveness. 
a Adjusted for age group, sex, month, pilot area and surveillance scheme. 
b Unadjusted 95% confidence interval. 
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c Individuals older than six months of age with underlying clinical disease such as chronic heart or respiratory 
disease that put the patient at increased risk of serious illness from influenza or where influenza may 
exacerbate the underlying disease itself. 
TABLE 5. Adjusted vaccine effectiveness estimates for influenza by age, type of vaccine and 
pilot area in < 18 year olds, United Kingdom, October 2014 to April 2015 (n = 701) 
Factor Level 
Adjusted VEa% (95% CI) by type 
A A(H3N2) B 
Age 2,3,4 years 58.5 (−31.4 to 86.9) 69.2 (−30.9 to 92.7) 100 (−82.5 to 100)b 
2,3,4 years intranasal 52.5 (−54.3 to 85.4) 65.7 (−50.1 to 92.1) 100 (−112.8 to 100)b 
< 18 years intranasal 31.2 (−29.5 to 63.4) 35.0 (−29.9 to 67.5) 100 (17 to 100)b 
< 18 years injection −69.4 (−409.3 to 43.7) −73.2 (−456.9 to 46.2) −123.7 (−1,343 to 65.3) 
< 18 17.5 (−41.1 to 51.7) 19.1(−44.1 to 54.6) 59.4(−48.1 to 88.8) 
Pilot 
area 
Non-pilot 38.1 (−64.7 to 76.7) 37.9 (−77.6 to 78.3) 50 (−205.4 to 91.8) 
Pilot 5.9 (−82 to 51.4) 5.4 (−92.4 to 53.4) 76.9 (−99.4 to 97.3) 
CI: confidence interval;; RCGP: Royal College of General Practitioners Royal College of General Practitioners 
Research and Surveillance Centre; SMN Specialist Microbiology Network; VE: vaccine effectiveness. 
a Adjusted for age group, sex, month, pilot area and surveillance scheme. 
b Unadjusted Cornfield 95% confidence interval. 
Vaccine effectiveness against influenza A virus infection 
The adjusted overall VE against influenza A was 29.9% (95% CI: 10.5 to 45.1), very similar to 
the estimate seen specifically for A(H3N2) of 29.3% (95% CI: 8.6, 45.3) (Table 3) reflecting the 
dominance of A(H3N2). 
The VE for A(H3N2) for the period October 2014 to January 2015 was 23.6% (95% CI: −2.9 to 
43.2) compared with 47.8% (95% CI: 10 to 69.7) for the period February to April 2015. VE for 
A(H3N2) for those vaccinated within three months of onset of illness was 24.6% (95% CI: −2.7 
to 44.6) compared with 34.4% (95% CI: 3.5 to 55.4) for those vaccinated more than three 
months before onset of illness. 
For those aged 18 years and over, the influenza A VE was 30.4% (95% CI: 8.4 to 47.2) and for 
A(H3N2), it was 29.4% (95% CI: 5.8 to 47.1) (Table 4). The results were very similar for 18–44, 
45–64 and ≥65 year olds, although with broader CIs for both influenza A and for A(H3N2). The 
VE against influenza A in the specific inactivated influenza vaccine (IIV) target groups 
(aged ≥ 65 or in a clinical risk group) was 34.8% (95% CI: 3.1 to 56.2), with a similar result for 
A(H3N2). Although the VE showed some variability across the various surveillance schemes, 
this difference was not significant. 
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For those aged under 18 years, the influenza A VE was 17.5% (95% CI: −41.1 to 51.7) and for 
A(H3N2) 19.1% (95% CI: −44.1 to 54.6) (Table 5). There was no evidence of a significant 
difference in effectiveness in pilot and non-pilot areas. The estimate for vaccines administered 
by injection (VE = −69.4% (95% CI: −409.3 to 43.7%) was non-significantly lower than for 
vaccine administered intranasally (VE = 31.2% (95% CI: −29.5 to 63.4). The estimates were 
very similar for A(H3N2) compared with those for influenza A overall. The results were also 
similar for the sub-analysis in 2–4 year olds, with more uncertainty. 
A regression analysis of the viral load (Ct values) in the A(H3N2) unvaccinated (n = 227) and 
vaccinated (n = 73) laboratory-confirmed cases received through the RCGP sentinel scheme in 
England, taking into account the number of days between onset and swab, found no 
statistically significant difference (p = 0.266) between the two groups. The mean difference in 
Ct values (not vaccinated – vaccinated) was −0.668 (95% CI: −1.848 to 0.512). 
Vaccine effectiveness against influenza B virus infection 
The adjusted overall VE against influenza B was 46.3% (95% CI: 13.9 to 66.35 (Table 3). The VE 
for influenza B for those aged 18 and over was 43.6% (95% CI: 5.5 to 66.3), with similar results 
for the 18–44 and 45–64 age groups, although with broader confidence intervals. 
The VE against influenza B in the vaccine target group (aged ≥ 65 or in a risk group) was 15.5% 
(95% CI: −107.6 to 65.6). Influenza B VE also showed some variability across the schemes 
although this difference was not significant (Table 4). 
VE for those aged under 18 years of age for influenza B was 59.4% (95% CI: −48.1 to 88.8), 
with the estimate for vaccine administered by injection (VE = −123.7% (95% CI: −1,343 to 65.3) 
lower, but not statistically significant, compared with that for vaccine administered 
intranasally, which did show evidence of significant protection (VE = 100%, 95% CI: 17 to 
100.0). The results were similar for the sub-analysis in 2–4 year olds. 
A sensitivity analysis for influenza A and B including all discarded samples (n = 922) due to late 
sampling (more than seven days after onset) did not lead to large changes in these point 
estimates, but slightly narrowed confidence intervals (data not shown). 
Discussion 
This study presents the end of season VE results for the 2014/15 season, when the UK 
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experienced circulation of both a drifted influenza A(H3N2) strain, followed by a drifted 
influenza B strain. This occurred in a season with a newly introduced universal paediatric 
influenza vaccination programme with a recently licensed live attenuated influenza vaccine. 
Our analysis finds that influenza A(H3N2) VE, unlike that for influenza B, was low, though 
nonetheless effective, in key target groups. Influenza B effectiveness was preserved despite 
the apparent drift of the main circulating B strains from the associated vaccine strain. Finally, 
there was a suggestion of effectiveness of LAIV in children against both influenza A and B. 
The UK, as several other northern hemisphere countries, experienced circulation of an 
antigenically and genetically drifted A(H3N2) strain, which was associated in particular with 
impact in the elderly, with levels of excess mortality higher than seen in the last substantial 
A(H3N2) season in 2008/09 [1,4]. The VE results presented in this paper indicate an overall 
effectiveness against medically attended laboratory-confirmed influenza in primary care of ca 
30%, which although lower than would be anticipated for a well- or moderately matched 
influenza vaccine, still indicates some clinically beneficial protection against the drifted strain. 
The age-specific estimates in the over 18 year olds (which will represent the effect of IIV) were 
broadly similar in the elderly and clinical at-risk groups. These end-of-season VE results, 
although low, are non-significantly higher than the mid-season point-estimate (of 3.4%) 
undertaken in January 2015 had suggested [5], and which had mirrored the findings 
elsewhere, in particular in Canada and North America [14,15]. Previous interim, mid-season 
estimates have usually provided a good indication of the final end-of-season measure, albeit 
with more uncertainty as they are based on a smaller sample size. The apparent difference 
this season could be due to a range of potential factors. The higher overall VE will be partially 
explained by the higher VE against influenza B which circulated later in the season, though 
this will not explain the difference in the point estimate for influenza A. One explanation for 
this observation might be changes in the circulation of A(H3N2) genetic sub-groups over the 
season, however there was no significant change in the monthly proportion of A(H3N2) for 
genetic groups 3C.3 and 3C.2a (data not shown) over the season, and random variation seems 
to provide the most likely explanation for our observed non-significant difference between VE 
at the middle and the end of the season. The mid-season estimates, with all their uncertainty, 
did nonetheless provide an early indication of lower effectiveness of the A(H3N2) component 
of the seasonal influenza vaccine and was important for public health action purposes to 
highlight the value of other interventions, in particular use of antivirals for treatment and 
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prophylaxis. 
Influenza A(H3N2) is generally considered to be associated with more severe disease in the 
elderly and the lower VE seen this season is likely to have been a contributory factor to the 
relatively severe impact of influenza observed this year. The last intense H3N2 season was in 
2008/09, where even in a season with a moderately matched H3N2 vaccine component with 
high coverage in the elderly, significant levels of excess mortality in the > 65 year olds was still 
seen [16]. These observations highlight the limitations of the traditional, selective influenza 
vaccination policy of targeting groups at higher risk of severe disease such as the elderly and 
were part of the rationale for the introduction of the live attenuated influenza vaccination 
programme for healthy children, which attempts to not only provide direct protection to the 
children themselves, but to also reduce transmission of influenza and thus provide indirect 
protection to the rest of the population. 
The main circulating influenza B strain this season was also drifted, with the dominant 
circulating B strain being of the B/Yamagata/16/88 lineage, but with reduced antigenicity to 
the 2014/15 northern hemisphere B/Yamagata-lineage vaccine virus, 
B/Massachusetts/2/2012 [1]. However, despite this virological finding, the overall influenza B 
VE was still moderately high at almost 50% effectiveness against the main circulating B strains 
and highlights the importance of observational VE studies to fully understand the clinical 
impact of drift when it occurs, and also the fact that tri/quadrivalent influenza vaccines 
provide potential protection against all these seasonal influenza types and subtypes. It is also 
important to note that the B viruses circulating this season are also antigenically similar to 
B/Phuket/3073/2013, the influenza B/Yamagata lineage virus selected for 2015/16 northern 
hemisphere influenza vaccines [17]. 
It is important to note that several of the sub-analyses, particularly stratifying VE by age, pilot 
area and scheme, result in estimates with lower precision. There were no significant 
differences in VE by these co-variates although the point estimates for VE against influenza A 
were different. These differences are likely to be chance fluctuations due to small numbers 
and highlight the need for large numbers of swabs to improve the power of such subgroup 
analyses. 
Despite these limitations, for the under 18 year olds, our results provide evidence of 
significant effectiveness for the live attenuated intranasally administered vaccine for influenza 
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B, albeit based on limited numbers. The LAIV VE estimate for influenza A indicated non-
significant protection and is congruent with the published literature indicating that LAIV can 
provide cross-protection against drifted strains [18-20]. Although the US [18], has dropped its 
preferential recommendation for the use of LAIV in children, the UK findings are particularly 
encouraging for this season, with the circulation of both A(H3N2) and B drifted strains and 
support the rationale for the introduction of the universal paediatric programme. Further 
work is underway to examine the population impact of the childhood influenza vaccine 
programme by comparing pilot and non-pilot school age programme areas in England and 
across the UK to investigate in particular the presence and size of any indirect effects of the 
programme. 
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